View Older Stories View More Recent Stories
-
Axsome Therapeutics (AXSM) Settles Sunosi Patent Litigation with Hikma Pharmaceuticals USA
-
Axsome Therapeutics (AXSM) Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
-
Axsome Therapeutics (AXSM) PT Raised to $212 at Mizuho, Top Pick
-
Axsome Therapeutics (AXSM) Announces SYMBRAVO Achieves Primary Endpoint in the EMERGE Phase 3 Trial
-
Mizuho Reiterates Outperform Rating on Axsome Therapeutics (AXSM)
-
Axsome Therapeutics (AXSM) PT Raised to $192 as RBC Capital Sees 'Further Room For Upside'
-
Axsome Therapeutics (AXSM) PT Raised to $153 at Needham
-
Cantor Fitzgerald Reiterates Overweight Rating on Axsome Therapeutics (AXSM)
-
Axsome Therapeutics (AXSM) PT Raised to $200 at Truist Securities
-
Axsome Therapeutics (AXSM) Misses Q4 EPS by 58c
-
Axsome Therapeutics (AXSM) PT Raised to $133 at UBS
-
H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
-
Axsome Therapeutics (AXSM) PT Raised to $195 at Mizuho
-
Axsome Therapeutics (AXSM) PT Raised to $190 at TD Cowen, Top Pick
-
Deutsche Bank Starts Axsome Therapeutics (AXSM) at Buy
-
Axsome Therapeutics (AXSM) PT Raised to $167 at BofA Securities
-
Truist Securities Reiterates Buy Rating on Axsome Therapeutics (AXSM)
-
Axsome Therapeutics (AXSM) Announces Settlement Agreement Resolving AUVELITY Patent Litigation
-
Axsome Therapeutics (AXSM) PT Raised to $143 at RBC Following Symbravo's Approval
-
Axsome Therapeutics (AXSM) PT Raised to $190 at Truist, Citing 'Symbravo's Bright Commercial Prospects'
-
Axsome Therapeutics (AXSM) PT Raised to $137 at Mizuho
-
Axsome Therapeutics (AXSM) Hosts SYMBRAVO FDA Approval Virtual Investor Event with Expert Thought Leader
-
Axsome Therapeutics (AXSM) PT Raised to $190 at H.C. Wainwright
-
Axsome Therapeutics (AXSM) Announces FDA Approval of SYMBRAVO for the Acute Treatment of Migraine with or without Aura in Adults
-
Cantor Fitzgerald provides update on Biotechnology stocks
-
Axsome Therapeutics (AXSM) PT Raised to $155 at TD Cowen
-
H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
-
Axsome Therapeutics (AXSM) PT Raised to $180 at Truist, Reflecting Raised AXS-05 Estimates
-
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
-
Axsome Therapeutics (AXSM) PT Raised to $180 at Truist Securities
-
Piper Sandler Highlights NBIX, ITCI, ALKS, AXSM as High Conviction Ideas in Biotechnology
-
Axsome Therapeutics (AXSM) PT Raised to $124 at Cantor Fitzgerald
-
H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
-
Axsome Therapeutics (AXSM) PT Lowered to $122 at Mizuho
-
Baird Reiterates Outperform Rating on Axsome Therapeutics (AXSM)
-
Leerink Partners Reiterates Outperform Rating on Axsome Therapeutics (AXSM)
-
Axsome Therapeutics (AXSM) call put ratio 1.2 calls to 1 put as share price down 6.4%
-
Guggenheim Reiterates Buy Rating on Axsome Therapeutics (AXSM)
-
Axsome Therapeutics (AXSM) Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
-
RBC report: Biotech faces both uncertainty and growth opportunities in 2025
-
RBC Capital's Game Changers: 'Disruptive Forces in Biotech'
-
RBC Capital's Global Biotech Outlook Report: 'Top 2025 Ideas'
-
Axsome Therapeutics (AXSM) PT Raised to $124 at Mizuho
-
Axsome Therapeutics (AXSM) Announces AXS-12 Achieves Primary Endpoint
-
H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
-
Axsome Therapeutics (AXSM) PT Raised to $132 at RBC Capital
-
Axsome Therapeutics (AXSM) PT Raised to $135 at Guggenheim
-
Truist Securities Reiterates Buy Rating on Axsome Therapeutics (AXSM)
-
Here's the updated Mizuho's Top Picks List
-
Mizuho Reiterates Outperform Rating on Axsome Therapeutics (AXSM)
